"Not Imaging. Imaging is essentially dead because of the inability to obtain a patent. Other companies already have imaging patents using the receptor alpha fetoprotein. Most likey, Goshen is doing additional testing on the saliva test."
Hey...How many times do people have to point out that RECAF and AFP are not the same!!!! Geez.
"RECAF is a receptor protein that binds and takes up AFP, a circulating fetal protein. RECAF and AFP should not be confused; the latter is a liver and testicular cancer marker known since 1963 whereas RECAF is an emerging broad-spectrum cancer marker."
"AFP works in the fetus as albumin does in the adult: Both bind and carry other, smaller molecules, including fatty acids.2 In vitro experiments have shown that after binding to RECAF, AFP penetrates the cell via coated pits, releases its load of fatty acids, and then leaves immunologically intact, likely ready to fetch another fatty acid molecule.3-5 The uptake of AFP, and hence the expression of RECAF, is related to the degree of cell differentiation: When a given fetal organ or tissue has reached a certain maturity, AFP is no longer taken up even if it is present in high concentrations in the extracellular fluid.6-8 Since cancer cells are poorly differentiated, it was first postulated and then demonstrated that they reexpress RECAF; hence, RECAF behaves as an oncofetal antigen.9,10 The AFP uptake by fetal cells occurs in most organs and tissues; therefore, RECAF, which mediates the uptake, has been shown to be reexpressed in many types of cancers.11-16"
News 
Market Data 
Discover 
AI
